Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey

Table 2 Characteristics of icatibant-treated attacks in patients with and without LTP

Characteristic	Attacks With LTP	Attacks Without LTP	Total
Patients, n	171	323	448^a
Attacks, n (%)	973 (30.1)	2255 (69.9)	3228
Attack severity, n (%)^b
n^c	813	2029	2842
Very mild	6 (0.7)	29 (1.4)	35 (1.2)
Mild	65 (8.0)	161 (7.9)	226 (8.0)
Moderate	243 (29.9)	759 (37.4)	1002 (35.3)
Severe	356 (43.8)	803 (39.6)	1159 (40.8)
Very severe	143 (17.6)	277 (13.7)	420 (14.8)
Attack site, n (%)
n^c	967	2222	3189
Skin	339 (35.1)	669 (30.1)	1008 (31.6)
Abdomen	460 (47.6)	1158 (52.1)	1618 (50.7)
Larynx	29 (3.0)	110 (5.0)	139 (4.4)
Other organs^d	23 (2.4)	52 (2.3)	75 (2.4)
Multiple sites	116 (12.0)	233 (10.5)	349 (10.9)
Type of administration, n (%)
n^c	923	2153	3076
Self-administration	705 (76.4)	1666 (77.4)	2371 (77.1)
HCP	218 (23.6)	487 (22.6)	705 (22.9)

Analysis included attack data for patients who were or were not receiving LTP at the time of the attack(s) and who were treated with icatibant for acute attacks
HCP health care provider, LTP long-term prophylaxis
^aSome patients reported attacks with LTP as well as without LTP
^b P = 0.147 for comparison of very mild/mild/moderate versus severe/very severe attacks
^cExcludes attacks with missing or unknown data
^dOther organs affected by ≥2 attacks include tongue, bladder, esophagus, lungs, respiratory tract, breast, genitals, testicles, bowel, stomach, uvula, joints, and brain

ISSN: 1710-1492